Psychemedics Net Worth
Psychemedics Net Worth Breakdown | PMD |
Psychemedics Net Worth Analysis
Psychemedics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Psychemedics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Psychemedics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Psychemedics' net worth analysis. One common approach is to calculate Psychemedics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Psychemedics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Psychemedics' net worth. This approach calculates the present value of Psychemedics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Psychemedics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Psychemedics' net worth. This involves comparing Psychemedics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Psychemedics' net worth relative to its peers.
Enterprise Value |
|
To determine if Psychemedics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Psychemedics' net worth research are outlined below:
| The company reported the last year's revenue of 22.1 M. Reported Net Loss for the year was (4.15 M) with profit before taxes, overhead, and interest of 9.29 M. | |
| Psychemedics has about 1.79 M in cash with (1.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
| Psychemedics has a poor financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from accesswire.com: PMD Device Solutions Announces Delay to Q3 2024 Quarterly Report |
Psychemedics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Psychemedics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Psychemedics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Psychemedics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Psychemedics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Psychemedics backward and forwards among themselves. Psychemedics' institutional investor refers to the entity that pools money to purchase Psychemedics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2024-06-30 | 11.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 6 K | Tower Research Capital Llc | 2024-06-30 | 3.6 K | Advisor Group Holdings, Inc. | 2024-06-30 | 257 | Caldwell Sutter Capital Inc | 2024-09-30 | 250 | Fmr Inc | 2024-09-30 | 100.0 | Royal Bank Of Canada | 2024-06-30 | 50.0 | Bank Of America Corp | 2024-06-30 | 39.0 | Northwestern Mutual Wealth Management Co | 2024-06-30 | 15.0 | 22nw, Lp | 2024-06-30 | 274.4 K | Renaissance Technologies Corp | 2024-09-30 | 270.9 K |
Follow Psychemedics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 13.79 M.Market Cap |
|
Project Psychemedics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.32) | |
| Return On Capital Employed | (0.38) | (0.36) | |
| Return On Assets | (0.34) | (0.32) | |
| Return On Equity | (0.62) | (0.59) |
When accessing Psychemedics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Psychemedics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Psychemedics' profitability and make more informed investment decisions.
Please note, the presentation of Psychemedics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Psychemedics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Psychemedics' management manipulating its earnings.
Evaluate Psychemedics' management efficiency
Psychemedics has Return on Asset of (0.1624) % which means that on every $100 spent on assets, it lost $0.1624. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6133) %, meaning that it generated no profit with money invested by stockholders. Psychemedics' management efficiency ratios could be used to measure how well Psychemedics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.32. The current year's Return On Capital Employed is expected to grow to -0.36. At present, Psychemedics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 663.6 K, whereas Other Assets are forecasted to decline to about 1.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.16 | 1.50 | |
| Tangible Book Value Per Share | 1.16 | 1.50 | |
| Enterprise Value Over EBITDA | (69.02) | (65.57) | |
| Price Book Value Ratio | 2.55 | 2.42 | |
| Enterprise Value Multiple | (69.02) | (65.57) | |
| Price Fair Value | 2.55 | 2.42 | |
| Enterprise Value | 23.8 M | 44.4 M |
Psychemedics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 0.6895 | Revenue 20.8 M | Quarterly Revenue Growth (0.15) | Revenue Per Share 3.586 | Return On Equity (0.61) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Psychemedics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Psychemedics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Psychemedics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kamin Peter over a month ago Acquisition by Kamin Peter of 627 shares of Psychemedics at 6.52 subject to Rule 16b-3 | ||
Weinert Fred J over three months ago Disposition of 1000 shares by Weinert Fred J of Psychemedics subject to Rule 16b-3 | ||
Kamin Peter over three months ago Discretionary transaction by Kamin Peter of tradable shares of Psychemedics subject to Rule 16b-3 | ||
Shoemaker Shannon over a year ago Psychemedics exotic insider transaction detected | ||
Weisenhoff Michael over a year ago Acquisition by Weisenhoff Michael of 4000 shares of Psychemedics subject to Rule 16b-3 | ||
Weisenhoff Michael over a year ago Psychemedics exotic insider transaction detected | ||
Michael Schaffer over a year ago Payment of 375 shares by Michael Schaffer of Psychemedics subject to Rule 16b-3 | ||
Michael Schaffer over a year ago Payment of 337 shares by Michael Schaffer of Psychemedics subject to Rule 16b-3 | ||
Fred Weinert over a year ago Acquisition by Fred Weinert of 1800 shares of Psychemedics subject to Rule 16b-3 |
Psychemedics Corporate Filings
8K | 25th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 18th of November 2024 Other Reports | ViewVerify | |
| 8th of November 2024 Other Reports | ViewVerify | |
| 18th of October 2024 Other Reports | ViewVerify |
Psychemedics Earnings per Share Projection vs Actual
Psychemedics Corporate Management
| Michael Schaffer | VP of Laboratory Operations | Profile | |
| Michael Weisenhoff | Principal Manager | Profile | |
| Charles IV | Ex VP | Profile | |
| Shannon Shoemaker | Chief Officer | Profile | |
| Werner Baumgartner | Founder | Profile | |
| Annette Baumgartner | Founder | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Psychemedics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Psychemedics Stock refer to our How to Trade Psychemedics Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psychemedics. If investors know Psychemedics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psychemedics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Earnings Share (0.51) | Revenue Per Share 3.586 | Quarterly Revenue Growth (0.15) | Return On Assets (0.16) |
The market value of Psychemedics is measured differently than its book value, which is the value of Psychemedics that is recorded on the company's balance sheet. Investors also form their own opinion of Psychemedics' value that differs from its market value or its book value, called intrinsic value, which is Psychemedics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psychemedics' market value can be influenced by many factors that don't directly affect Psychemedics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Psychemedics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Psychemedics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psychemedics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.